Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin... It belongs to the lantibiotics.
- Mechanism
- Curator reviewed
Duramycin becomes deposited in cellular membranes where it binds to phosphatidylethanolamine. It may thereby change biophysical membrane properties and perturb ion channel function. Duramycin stimulates secretion of electrically charged atoms (ions) of chloride from epithelial cells in the lungs. Increased chloride secretion is accompanied by obligatory increase in water secretion from same cells. This may prevent the thickening of lung secretions and prevent further mucus build up and its progressive contribution to lung tissue damage.
- Primary indication
- Investigated for use/treatment in cystic fibrosis and eye disorders/infections.Curator reviewed
- Formula / weight
- C89H125N23O25S3 · 2013.3 g/mol (avg)
- Also known as
- Duramycin · Leucopeptin
- Code names
- Antibiotic PA 48009 · MOLI-1901
Resolves to
SFWLDKQAUHFCBS-AOEYGKNYSA-NSMILESCC(C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]2NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]3CNCCCC[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS[C@H]4C)C(=O)N[C@@H](CS[C@H]2C)C(=O)N3)NC1=O)[C@@H](O)C(O)=O)C(O)=OWhat you can answer from here — as of July 03, 2026
Which drugs share a target with Lancovutide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account